In Vitro analysis of TNF-alpha with the drug Paclitaxel in OSCC cells before and after the treatment
Abstract
OBJECTIVE To Invitro analysis of the drug Paclitaxel in Oral Squamous Cell Carcinoma cells.Oropharyngeal cancer, also known as Oral Squamous Cell Carcinoma (OSCC), is a cancer derived from squamous cell in the oral cavity or oropharyngeal. Globally, it is a major public health problem whose incidence has gone up greatly. For the treatment of OSCC, a multi discipline approach is used such as surgery, radiotherapy and chemotherapy. The use of Paclitaxel in fighting OSCC has been recently investigated by researchers. Therefore, in vitro studies help in testing the potential effects of Paclitaxel on the OSCC (oral squamous cell carcinoma) cells, in a strictly controlled environment. Such studies shed light on how the drug works, its anti-tumor activity, and its utility as an adjuvant in OSCC therapy.
MATERIALS AND METHODS Cell culture and treatment involves the following steps:KB cells were treated with paclitaxel.Cell proliferation was performed by MTT assay RNA isolation is made using Trizol method .cDNA conversion has been conducted. Real time- polymerase chain reaction was used for the analysis of gene expression Statistical analyses were done using SPSS software.Culture of the tissues and cisplatin treatment:OSCC cells were obtained from the Department of Oral Surgery at Saveetha Dental College and Hospital, and they were grown following standard guidelines .In the drug treatment experiments, cells underwent paclitaxel for 48 hours.
RESULT In this microscopic view OSCC exhibits squamous differentiation by formation of keratin and intercellular bridges. When grown in vitro, these cells stick to the culture flask and develop into a monolayer.. The proliferation rate has significantly reduced after treatment with packitaxel.The expression of TNF-a was significantly reduced after the treatment when compared to the normalKB cells
CONCLUSION Paclitaxel reduces the proliferation of kB cells.It drastically reduce cell proliferation within the first 12 hrs of treatment and later plateau state was observed.Thus we conclude that TNF- alpha is reduced in the presence of paclitaxel in OSCC cells
References
2. Blumenthal, R.D. (2008) Chemosensitivity: Volume I: In Vitro Assays. Springer Science & Business Media.
3. Bocci, G. and Francia, G. (2014) Metronomic Chemotherapy: Pharmacology and Clinical Applications. Springer.
4. Carcinogen-Driven Mouse Models of Oncogenesis (2021). Academic Press.
5. Choi, H.S. et al. (2020) ‘Increased FOXM1 Expression by Cisplatin Inhibits Paclitaxel-Related Apoptosis in Cisplatin-Resistant Human Oral Squamous Cell Carcinoma (OSCC) Cell Lines’, International journal of molecular sciences, 21(23). Available at: https://doi.org/10.3390/ijms21238897.
6. ‘Circulatory microRNAs inhibition and its signaling pathways in the treatment of oral squamous cell carcinoma (OSCC)’ (2022) Oral oncology, 126, p. 105763.
7. ‘Expression analysis of transforming growth factor beta (TGF-β) in oral squamous cell carcinoma’ (2024) Oral Oncology Reports, 9, p. 100195.
8. Fribley, A. (2016) Targeting Oral Cancer. Springer.
9. Han, H.-Y. et al. (2016) ‘Kochia scoparia induces apoptosis of oral cancer cells in vitro and in heterotopic tumors’, Journal of ethnopharmacology, 192, pp. 431–441.
10. Kii, T., Sakuma, K. and Tanaka, A. (2021a) ‘Optimal Contact Concentration of Paclitaxel in the Collagen Gel Droplet-Embedded Culture Drug Sensitivity Test for Human Oral Squamous Cell Carcinoma and Evaluation of Combination with Cetuximab’, Chemotherapy, 65(5-6), pp. 147–157.
11. Kii, T., Sakuma, K. and Tanaka, A. (2021b) ‘PTEN Is Activated by the Addition of Cetuximab to Paclitaxel in Oral Squamous Cell Carcinoma’, Anticancer research, 41(7), pp. 3363–3370.
12. Kumar, V.B. et al. (2021) ‘7-Epitaxol Induces Apoptosis and Autophagy in Head and Neck Squamous Cell Carcinoma through Inhibition of the ERK Pathway’, Cells , 10(10). Available at: https://doi.org/10.3390/cells10102633.
13. Mallery, S.R. et al. (2019) ‘Fenretinide, Tocilizumab, and Reparixin Provide Multifaceted Disruption of Oral Squamous Cell Carcinoma Stem Cell Properties: Implications for Tertiary Chemoprevention’, Molecular cancer therapeutics, 18(12), pp. 2308–2320.
14. Meng, X. et al. (2021) ‘The role of non-coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential’, Cancer communications, 41(10), pp. 981–1006.
15. Panta, P. (2019) Oral Cancer Detection: Novel Strategies and Clinical Impact. Springer.
16. Parsons, R.A. (2007) Progress in Cancer Drug Resistance Research. Nova Publishers.
17. Reinhold, U. and Tilgen, W. (2002) Chemosensitivity Testing in Oncology. Springer Science & Business Media.
18. ‘Reviewing the potential application of miR-21 inhibitors in oral cancer therapeutics’ (2022) Oral oncology, 125, p. 105713.
19. Sawatani, Y. et al. (2020) ‘Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro’, International journal of molecular sciences, 21(17). Available at: https://doi.org/10.3390/ijms21176292.
20. September 2021 - Volume 74 - Issue 3 : Hepatology (no date). Available at: https://journals.lww.com/hep/toc/2021/09000 (Accessed: 9 February 2024).
21. Song, J.M. et al. (2019) ‘Oral Administration of , a Major Pathogen of Chronic Periodontitis, Promotes Resistance to Paclitaxel in Mouse Xenografts of Oral Squamous Cell Carcinoma’, International journal of molecular sciences, 20(10). Available at: https://doi.org/10.3390/ijms20102494.
22. Wasan, K.M. and Badea, I. (2019) Drug Delivery Technology Development in Canada. MDPI.
23. Yuzhalin, A. and Kutikhin, A. (2014) Interleukins in Cancer Biology: Their Heterogeneous Role. Academic Press.
